— MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected.
— The results were driven by increased total revenues from higher Afrezza commercial demand and from the licensing and research agreements with United Therapeutics.
— Net revenues soared by 227% to $14.6 million versus $15.08 million expected.
— Afrezza net revenue jumped by 46% primarily driven by higher product demand, including the first shipment to Brazil, a more favorable mix of Afrezza cartridges and price.
— Collaborations and services revenue surged to $8.19 million from $82,000 last year, primarily driven by the license agreement with United Therapeutics, which began in the fourth quarter of 2018.
— Research and development (R&D) expense decreased by 23% year-over-year, primarily attributable to a decline in clinical trial spending.
Most Popular
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Target (TGT): A look at some of the challenges faced by the retailer in 3Q24
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and
